Journal
BIOMATERIALS
Volume 269, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2020.120630
Keywords
Dual-modal; PET; Near-infrared fluorescence; Immune cell labeling; Nanomedicine; Tracking
Funding
- Scientific and Technological Research Council of Turkey (TUBITAK) [BIDEB-2219] Postdoctoral Research program
- United States NIH/NCI Cancer Center Support Grant [P30 CA008748]
Ask authors/readers for more resources
The adoptive cell transfer of targeted chimeric antigen receptor (CAR) T cells is a promising cancer therapy, and a dual-modal PET/NIRF nanoparticle-based imaging agent has been developed to monitor their biodistribution and fate in vivo, providing a new approach for imaging technology in other cancer models.
Adoptive cell transfer of targeted chimeric antigen receptor (CAR) T cells has emerged as a highly promising cancer therapy. The pharmacodynamic action or CAR T cells is closely related to their pharmacokinetic profile; because of this as well as the risk of non-specific action, it is important to monitor their biodistribution and fate following infusion. To this end, we developed a dual-modal PET/near infrared fluorescent (NIRF) nanoparticlebased imaging agent for non-genomic labeling of human CAR T cells. Since the PET/NIRF nanoparticles did not affect cell viability or cytotoxic functionality and enabled long-term whole-body CAR T cell tracking using PET and NIRF in an ovarian peritoneal carcinomatosis model, this platform is a viable imaging technology to be applied in other cancer models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available